Novel composed galactosylated nanodevices containing a ribavirin prodrug as hepatic cell-targeted carriers for HCV treatment

Journal of Biomedical Nanotechnology

Volumn 9, Issue 6, 2013, Pages 1107-1122

  Craparo, Emanuela Fabiola ^a   Teresi, Girolamo ^a   Licciardi, Mariano ^a   Bondí, Maria Luisa ^b   Cavallaro, Gennara ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR   (Italy)

Author keywords

Active targeting; Galactosylated nanoparticles; Hepatic cell targeted carriers; Hepatitis C; Ribavirin tripalmitate

Indexed keywords

ACTIVE TARGETING; CARBOHYDRATE RECEPTORS; COMPETITIVE INHIBITION ASSAYS; DRUG DELIVERY STRATEGIES; ENZYMATIC ACTIVITIES; GALACTOSYLATED NANOPARTICLES; HEPATITIS C; RIBAVIRIN;

AMIDES; COPOLYMERS; DIALYSIS; DRUG DELIVERY; PHOSPHOLIPIDS;

NANOPARTICLES;

ALPHA,BETA POLY(N 2 HYDROXYETHYL) [[(2 AMINOETHYLCARBAMATE)] CO [2 (1,2 DIPALMITOYL GLYCERO 3 PHOSPHOETHANOLAMINE N SUCCINYL) AMIDOETHYLCARBAMATE]] ASPARTAMIDE COPOLYMER; DRUG CARRIER; NANOPARTICLE; POLYMER; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; DIALYSIS; DRUG RELEASE; ENZYME ACTIVITY; HEMOLYSIS; HYDROPHOBICITY; NANODEVICE; PARTICLE SIZE;

ANTIVIRAL AGENTS; DIFFUSION; GALACTOSE; HEP G2 CELLS; HEPATITIS C; HUMANS; MATERIALS TESTING; NANOCAPSULES; PRODRUGS; RIBAVIRIN;

EID: 84877816924     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1608     Document Type: Article

References (33)

1. T. Lammers, W. E. Hennink, and G. Storm, Tumour-targeted nano-medicines: Principles and practise. British Journal of Cancer 99, 392 (2008).
2. L. Li, H. Wang, Z. Y. Ong, K. Xu, P. L. R. Ee, S. Zheng, J. L. Hedrick, and Y.-Y. Yang, Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today 5, 296 (2010).
3. S. Azarmi, W. H. Roa, and R. Lobenberg, Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 60, 863 (2008).
4. E. F. Craparo, M. L. Bondì, G. Pitarresi, and G. Cavallaro, Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci. Ther. 17, 670 (2011).
5. F. Fay and C. J. Scott, Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 3, 381 (2011).
6. M. Talekar, J. Kendall, W. Denny, and S. Garg, Targeting of nanoparticles in cancer: Drug delivery and diagnostics. Anti-Cancer Drugs 22 949 (2011).
7. J. C. Wasmuth and C. Hepatitis, Epidemiology, transmission and natural history, Hepatology-A Clinical Textbook, 2nd edn., edited by S. Mauss, T. Berg, J. Rockstroh, C. Sarrazin, and H. Wedemeyer, Flying Publisher, Düsseldorf, German (2010), pp. 19-29.
8. M. J. Bouchard and S. Navas-Martin, Hepatitis B and C virus hepatocarcinogenesis: Lessons learned and future challenges. Cancer Lett. 305, 123 (2011).
9. A. L. Armstead and B. Li, Nanomedicine as an emerging approach against intracellular pathogens. Int. J. Nanomed. 6, 3281 (2011).
10. M. Cornberg, M. P. Manns, H. Wedemeyer, and C. Hepatitis, Standard of care, Hepatology-A Clinical Textbook, 2nd edn., edited by S. Mauss, T. Berg, J. Rockstroh, C. Sarrazin, H. Wedemeyer, Flying Publisher, Düsseldorf, German (2010), pp. 171-195.
11. F. Hashim, M. El-Ridy, M. Nasr, and Y. Abdallah, Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv. 17, 282 (2010).
12. T. Yasin, T. R. Riley, and I. R. Schreibman, Current treatment of choice for chronic hepatitis C infection. Infect. Drug Resist. 4, 11 (2011).
13. V. Loustaud-Ratti, A. Rosseau, P. Marquet, F Denis, and S. Alain, Ribavirin in chronic hepatitis C: Past and future. Expert Rev. Anti Infect. Ther 7, 249 (2009).
14. J. Wu, M. H. Nantz, and M. A. Zern, Targeting hepatocytes for drug and gene delivery: Emerging novel approaches and applications. Front. Biosci. 7, d717 (2002).
15. P. Marcellin, R. G. Gish, N. Gitlin, J. Heise, D. G. Halliman, E. Chun, and M. Rodriguez-Torres, Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naïve hepatitis C pazients. J. Hepatol. 52, 32 (2010).
16. T. Mickle and S. Guenther, Prodrugs of ribavirin with improved hepatic delivery PCT Int. Appl. WO 2006050421, A1 20060511 (2006).
17. M. Derudas, A. Brancale, L. Naesens, J. Neyts, J. Balzarini, and C. McGuigan, Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin. Bioorg. Med. Chem. 18, 2748 (2010).
18. F Li and J. Wang, Targeted delivery of drugs for liver fibrosis. Expert Opin. Drug Deliv. 6, 531 (2009).
19. L. Fiume and G. Di Stefano, Lactosaminatedhuman albumin, a hepatotropic carrier of drugs. European J. Pharm. Sci. 40, 253 (2010).
20. S. H. Medina, V. Tekumalla, M. V. Chevliakov, D. S. Shewach, W. D. Ensminger, and M. E. H. El-Sayed, N-acetylgalactosamine-functionalized dend 2: mers as hepatic cancer cell-targeted carriers. Biomaterials 32, 4118 (2011).
21. M. Licciardi, M. Campisi, G. Cavallaro, M. Cervello, A. Azzolina, and G. Giammona, Synthesis and characterization of polyaminoacidic polycations for gene delivery. Biomaterials 27, 2066 (2006).
22. C. Managit, S. Kawakami, F Yamashita, and M. Hashida, Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosilated liposomes. J. Pharm. Sci. 94, 2266 (2005).
23. G. Giammona, B. Carlisi, and S. Palazzo, Reaction of α,β- poly(N-2-hydroxyethyl)-DL-aspartamide with derivatives of carboxylic acids. J. Polym. Sci. Polym. Chem. Ed. 25, 2813 (1987).
24. E. F Craparo, M. C. Ognibene, M. P. Casaletto, G. Pitarresi, G. Teresi, and G. Giammona, Biocompatible polymeric micelles with polysorbate 80 for use in brain targeting. Nanotechnology 19, 485603 (2008).
25. A. Laurentin and C. A. Edwards, A microtiter modification of the anthrone-sulfuric acid colorimetric assay for glucose-based carbohydrates. Anal. Chem. 315, 143 (2003).
26. W.-J. Lin and M. H. Chen, Synthesis of multifunctional chitosan with galactose pendant as targeting ligand for glycoprotein receptor. Carbohydr. Polym. 67, 474 (2007).
27. E. F Craparo, G. Teresi, M. L. Bondi', M. Licciardi, and G. Cavallaro, Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids. Int. J. Pharm. 406, 135 (2011).
28. C. Vermehren, K. Jørgensen, R. Schiffelers, and S. Frokjaer, Activity of mammalian secreted phospholipase A2 from inflammatory peritoneal fluid towards PEG-liposomes. Early indications. Int. J. Pharm. 214, 93 (2001).
29. V. Y. Serebrov, D. I. Kuzmenko, P. G. Burov, and S. V. Novitsky, Activity of sphingomyelinase in rat liver in acute and chronic toxic hepatitis: Proportion between peroxidative and phospholipase pathways of lipid bilayer modification. Bull. Exp. Biol. Med. 147, 37 (2009).
30. B. Song, W. Zhang, R. Peng, J. Huang, T. Nie, Y. Li, Q. Jiang, and R. Gao, Synthesis and cell activity of novel galactosylated chitosan as a gene carrier. Colloid Surf. B-Biointerfaces 70, 181 (2009).
31. H. K. Cho, I. W. Cheong, J. M. Lee, and J. H. Kim, Polymeric nanoparticles, micelles and polymerosomes from amphiphilic block copolymers. Korean J. Chem. Eng. 27, 731 (2010).
32. X. Li, Q. Wu, Z. Chen, X. Gong, and X. Lin, Preparation, characterization and controlled release of liver-targeting nanoparticles from the amphiphilic random copolymer. Polymer 49, 4769 (2008).
33. H. Zheng, X. Zhang, F. Xiong, Z. Zhu, B. Lu, Y. Yin, P. Xu, and Y. Du, Preparation, characterization, and tissue distribution in mice of lactosaminated carboxymethyl chitosan nanoparticles. Carbohydr. Polym. 83, 1139 (2011).